Trial Profile

A phase 1 trial of VCA-894A for the treatment of CharcotMarie-Tooth disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VCA 894A (Primary)
Indications Charcot-Marie-Tooth disease
Focus Adverse reactions

Most Recent Events

10 Jun 2025 According to a Vanda Pharmaceuticals media release, first patient has been dosed in this trial.
07 May 2025 According to a Vanda Pharmaceuticals media release, VCA-894A expects to enroll the patient by mid-2025.
24 Feb 2025 According to a Vanda Pharmaceuticals media release, the drug is expected to be administered soon to the specific patient for whom it was developed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com